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Purpose: Anxiety can worsen prostate cancer patients’ decision making and quality of life. Early identification of anxiety disorders is 
thus very important for excellent prostate cancer treatment. This study aimed to determine the levels of anxiety in patients with early-
stage prostate cancer compared with advanced-stage disease. 
Methods: This cross-sectional study was performed at the Department of Urology, ‘Cipto Mangunkusumo’ Hospital, Faculty of Medicine, 
University of Indonesia. The subjects were early-stage prostate cancer patients and advanced-stage prostate cancer patients with 
bone metastatic lesions proved by bone scan. Comparative analysis was done to analyze anxiety scores assessed by use of an 11-item 
modified Memorial Anxiety Scale for Prostate Cancer (MAX-PC) questionnaire. We also assessed the relationship of the MAX-PC score 
with age, prostate-specific antigen (PSA) value, number of bone metastases, and pain. Data were analyzed by using the Statistical 
Package for the Social Sciences, version 17 (SPSS Inc.). 
Results: There were 34 subjects with early-stage prostate cancer and 34 subjects with advanced-stage prostate cancer. We found that 
the mean anxiety score was significantly lower (P=0.0001) in the early-stage prostate cancer group (8.32±3.65) than in the advanced-
stage prostate cancer group (12.61±4.56). Nine subjects had a pathological MAX-PC score (≥16), of whom 1 subject had early-stage 
disease and 8 subjects had advanced-stage disease. Furthermore, there were significant positive correlations (P<0.001) between 
MAX-PC score and visual analogue scale pain score (r=0.633), PSA value (r=0.263), and number of bone metastatic lesions (r=0.464). 
However, the correlation between age and anxiety score was not significant (P=0.170). 
Conclusions: The MAX-PC anxiety score was significantly associated with the stage of prostate cancer. Furthermore, visual analogue 
scale pain score, PSA value, and number of bone metastatic lesions can also affect the MAX-PC anxiety score. 
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INTRODUCTION
Prostate cancer is the most common carcinoma among men 
in Western countries, and the incidence rate is increasing in 
Asian countries [1]. Men diagnosed with prostate cancer have 
a higher anxiety level and a higher risk of developing depres-
sion than do healthy men [2]. They also have a tendency for 
suicide that is 4 times higher than the risk in healthy indi-
viduals [3]. Prostate cancer patients also experience serious 
challenges to their self-esteem [4,5], especially concerning 
their masculinity [6,7]. Some of the unpleasant experiences 
that prostate cancer patients may have are the fear of bearing 
their unpredictable future [8]; pain; fatigue; nausea (due to 
medication); loss of social and physical capabilities, especially 
sexual capability, as the result of hormonal therapy [9]; and 
erectile dysfunction, which occurs in 30% to 70% of patients 
who undergo prostate surgery [10,11]. The patient’s response 
to those unpleasant experiences may be a trigger of anxiety 
and depression in this population [12]. Anxiety and depres-
sion also affect the quality of life of patients with prostate 
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cancer, especially those receiving hormonal therapy [13]. Fur-
thermore, anxiety and depression can worsen the patient’s 
decision making. For these reasons, early identification of 
affective disorders is very important for making good prostate 
cancer treatment decisions [4,14]. Unfortunately, only a few 
studies about quality of life and the psychological character-
istics of prostate cancer patients have been conducted in Asia 
[15]. In general, those studies showed that the anxiety level 
of patients with cancer was proportional to the stage of the 
disease [16]. The aim of the present study was to determine 
the anxiety level of patients with early-stage prostate cancer 
compared with that of patients with advanced-stage disease 
at our institution.
MATERIALS AND METHODS
1. Patients
The subjects of this study were newly diagnosed patients with 
early-stage or advanced-stage prostate cancer registered in 
the Department of Urology, “Cipto Mangunkusumo” Hospi-
tal. Advanced-stage prostate cancer was defined as metastatic 
prostate cancer proved by bone scan. Exclusion criteria were 
subjects who could not communicate or fill out the anxiety or 
visual analogue scale (VAS) form.
2. Data collection
Subjects who met the inclusion criteria were requested to 
participate in this study. We collected data on age, anxiety scale 
score, pain VAS score, number of bone metastatic lesions, and 
prostate-specific antigen (PSA) value. Anxiety was assessed by 
use of the modified memorial anxiety scale for prostate can-
cer (MAX-PC) and pain was assessed by use of a VAS (score, 
1 to 10). The modified MAX-PC questionnaire consisted of 11 
questions, which are shown in the Appendix. The MAX-PC 
questionnaire was validated in a study assessing anxiety by 
Roth et al. [17] in New York and in a study by Van den Bergh 
et al. [18] in Rotterdam. The number of study subjects was 34 
with early-stage prostate cancer and 34 with advanced-stage 
prostate cancer. Subjects who had a MAX-PC score ≥  16 were 
classified in the pathological group [17-19]. Approval for this 
study was obtained from the health research ethics commit-
tee in the Faculty of Medicine, “Cipto Mangunkusumo” Hos-
pital, University of Indonesia.
3. Data analysis
Data were analyzed and presented in a frequency distribu-
tion table. Comparison of anxiety scores between early-stage 
prostate cancer patients and advanced-stage prostate cancer 
patients was performed by use of independent t-tests. If the 
independent t-test requirement was not met, the Mann-Whit-
ney test was used. The study confounding factors were VAS, 
PSA value, number of bone metastatic lesions, and age. The 
relationship between age, VAS, and PSA value with the anxi-
ety score was analyzed by using the Pearson correlation test. 
If the Pearson correlation test requirement was not met, the 
Spearman test was used. The data were analyzed by using the 
Statistical Package for the SPSS ver. 17 (SPSS Inc., Chicago, IL, 
USA). The analysis was considered significant if the P-value 
was < 0.05.
RESULTS 
Of the 68 subjects, there were 34 early-stage and 34 advanced-
stage prostate cancer patients. The mean age of the subjects 
was 67.99 ± 8.724 years. The mean MAX-PC score was 10.47 ± 
4.64. Of the 68 subjects, 59 subjects did not have a pathologi-
cal MAX-PC score (MAX-PC score < 16). Nine subjects, how-
ever, had pathological MAX-PC scores. Of those 9 subjects, 
1 subject was an early-stage prostate cancer patient and 8 
subjects were advanced-stage prostate cancer patients. The 
mean VAS score was 4.05 ± 1.99. Other characteristics of the 
data set can be seen in Table 1.
 As stated above, the mean MAX-PC score in this study 
was 10.47 ± 4.64, with a median value of 9 (range, 1–23), and 
the mean VAS score was 4.05 ± 1.99, with a median value of 
4 (range, 1–8). We found a significant difference in the anxi-
ety score and the mean VAS score between the groups with 
early-stage and advanced-stage prostate cancer. The mean 
anxiety score in the group of early-stage prostate cancer 
patients (8.32 ± 3.65) was significantly lower than the mean 
anxiety score in the advanced-stage prostate cancer group 
(12.61 ± 4.56). Analysis of this relationship is shown in Tables 
2 and 3.
 The relationship between confounding factors (age, VAS, 
PSA value, number of bone metastatic lesions) and the MAX-
Table 1. Subject characteristics in the early- and advanced-
stage prostate cancer groups
Characteristic
Early-stage  
prostate cancer
Advanced-stage  
prostate cancer
Mean Median Mean Median
Age (yr) 67.39 68.00 68.56 71.00
Prostate-specific  
antigen (ng/mL)
43.75 13.72 522.26 189.47
No. of bone  
metastatic lesion
NA NA 12.85 6.50
NA, not applicable.
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PC score was analyzed by using the Spearman test. This study 
found that the correlation between age and MAX-PC was not 
significant with no strong positive correlation. Interestingly, 
a significant association was found between VAS scores and 
the MAX-PC score (P < 0.001) with a very strong positive cor-
relation (r= 0.633), which could mean that the greater the VAS 
score the greater the MAX-PC score. These correlations are 
shown in Table 4.
DISCUSSION
Problems in treating cancer patients include not only the can-
cer itself, but also the quality of life and psychological problems 
of patients. Anxiety and depression are the most common 
psychological disorders in patients with cancer [17]. It has 
been reported that the level of anxiety and depression is high-
er in prostate cancer patients than in healthy men. The MAX-
PC is a valid and reliable method for identifying anxiety re-
lated to prostate cancer [19,20]. In this study, the mean MAX-
PC score was 10.47 ± 4.64. Similar results were reported by 
Van den Bergh et al. [20], who found a mean MAX-PC score 
of 9.3 ± 6.8. The analysis of the relationship between prostate 
cancer stage and anxiety scores showed a significant differ-
ence in the mean MAX-PC score (P= 0.0001) between the ear-
ly-stage prostate cancer group (8.32 ± 3.65) and the advanced-
stage prostate cancer group (12.61 ± 4.56). Vodermaier et al. 
[16] reported the same findings that anxiety symptoms were 
more commonly found in metastatic prostate cancer patients 
than in nonmetastatic prostate cancer patients.
 Another study by Bill-Axelson et al. [21] suggested that the 
hospitalization rate related to psychiatric symptoms (anxiety) 
will increase along with the diagnosis of prostate cancer. In 
patients with advanced-stage cancer, there would be more 
treatment for anxiety with a relative risk of 2.28 (95% confi-
dence interval, 1.45–3.57) compared with early-stage cancer 
[21]. The most common metastatic site of prostate cancer is 
bone. In prostate cancer, bone metastatic lesions result in lo-
calized pain [22]. In our study, the pain score (VAS) in patients 
with advanced-stage prostate cancer was significantly higher 
than that in patients with early-stage prostate cancer. In this 
study, there were some confounding variables significantly 
related to the MAX-PC score (P < 0.05). These were the level of 
pain (VAS score), PSA value, and number of bone metastatic 
lesions. The VAS score was significantly correlated with the 
anxiety level (MAX-PC score). Cancer pain in prostate cancer 
patients was considered to have a major effect on anxiety level 
(r = 0.633, P < 0.001); therefore, the proper management of 
pain is important. 
 The high level of anxiety could affect patient decision mak-
ing in determining the treatment of choice [19,23]. A study 
by Latini et al. [24] showed that early-stage prostate cancer 
patients who have a high level of anxiety tend to make an 
early decision for more aggressive therapy compared with 
undergoing active surveillance. The existence of this anxiety 
disorder along with depression would interfere in daily activi-
ties, reduce the quality of life, and increase the incidence of 
suicide of prostate cancer patients [3,7,9]. Factors that could 
increase the risk of anxiety in cancer patients are advanced 
stage of cancer, previous history of anxiety, lack of family sup-
port, activity limitations due to cancer, other comorbidities, 
and unresolved cancer pain [23]. In the National Compre-
hensive Cancer Network distress guideline version 2.2013, 
an indication for referring a cancer patient to mental health 
services or social work and counseling services is a Distress 
Thermometer value of 4 or more with social, family, physical, 
emotional, and other medical problems. In assessing prostate 
cancer–related anxiety, we have not yet found a cutoff score 
Table 2. Analysis of the relationship between prostate cancer 
stage and MAX-PC score
Prostate cancer stage MAX-PC value P-value
Early-stage 8.32±3.65 (1–19) 0.0001a)
Advanced-stage 12.61±4.56 (2–23)
Values are presented as mean±standard deviation (range).
MAX-PC, memorial anxiety scale for prostate cancer.
a)Mann-Whitney test.
Table 3. Comparison of mean VAS pain scores in the early- and 
advanced-stage prostate cancer groups
Prostate cancer stage Value P-value
Early-stage 3.32±1.77 (1–8) 0.002a)
Advanced-stage 4.79±1.96 (1–8)
Values are presented as mean±standard deviation (range).
VAS, visual analogue scale.
a)Mann-Whitney test.
Table 4. Correlation of MAX-PC scores with age, VAS, PSA value, 
and number of bone metastatic lesions
Variable
Correlation coefficient with 
MAX-PC score
P-value
Age 0.168 0.170a)
PSA 0.263 0.032a)
No. of bone  
metastatic lesion
0.464 <0.001a)
VAS 0.633 <0.001a)
MAX-PC, memorial anxiety scale for prostate cancer; VAS, visual ana-
logue scale; PSA, prostate-specific antigen.
a)Spearman test.
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on the MAX-PC for referral to mental health services (psy-
chiatry). Despite some research on the psychological needs 
of men with prostate cancer in Asian countries, it is difficult 
to draw clear conclusions about the impacts of prostate can-
cer on the psychological health of Asian men with prostate 
cancer [15]. Further investigations are required to determine 
the cutoff score on the MAX-PC questionnaire for referral to 
mental health services.
 The limitations of this study were the relatively small num-
ber of study subjects (34 patients in each group) and the lack 
of guidelines in terms of psychiatric treatment for patients 
with high levels of anxiety. This study also did not examine 
the effect of the high level of anxiety on patient quality of life 
and their therapy selection. Future studies should be con-
ducted to determine the cutoff value of MAX-PC score for re-
ferral by use of the MAX-PC instrument in combination with 
a psychiatric diagnostic instrument, such as the Mini-Inter-
national Neuropsychiatric Interview for The Diagnostic and 
Statistical Manual of Mental Disorders (MINI, DSM-IV). The 
MINI is a short, structured diagnostic interview developed in 
1990 by psychiatrists and clinicians in the United States and 
Europe for DSM-IV and International Statistical Classification 
of Diseases-10th revision psychiatric disorders [25].
 In conclusion, advanced-stage prostate cancer was sig-
nificantly related to a high level of anxiety (MAX-PC score). 
Furthermore, VAS scores, PSA value, and the number of bone 
metastatic lesions might affect the anxiety (MAX-PC score) 
of patients with prostate cancer. Study of larger populations 
should be done to acquire a cutoff value of the MAX-PC score 
for better management of mental health issues in prostate 
cancer patients.
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Appendix. Modified memorial anxiety scale for prostate cancer (MAX-PC). Below is a list of comments made by men about prostate 
cancer. Please indicate by circling the number next to each item how frequently these comments were true for you during the past 
week; not at all, rarely, sometimes, often
Not at all Rarely
Some-
times
Often
1. Any reference to prostate cancer brought up strong feelings in me. 0 1 2 3
2. Even though it’s a good idea, I found that getting a PSA test scared me. 0 1 2 3
3. Whenever I heard about a friend or public figure with prostate cancer, I got more anxious about my 
having prostate cancer.
0 1 2 3
4. When I thought about having a PSA test, I got more anxious about my having prostate cancer. 0 1 2 3
5. Other things kept making me think about prostate cancer. 0 1 2 3
6. I felt kind of numb when I thought about prostate cancer. 0 1 2 3
7. I thought about prostate cancer even though I didn’t mean to. 0 1 2 3
8. I had a lot of feelings about prostate cancer, but I didn’t want to deal with them. 0 1 2 3
9. I had more trouble falling asleep because I couldn’t get thoughts of prostate cancer out of my mind. 0 1 2 3
10. I was afraid that the results from my PSA test would show that my disease was getting worse. 0 1 2 3
11. Just hearing the words “prostate cancer” scared me. 0 1 2 3
Modified MAX-PC score ≥16 was the cutoff score for pathological prostate cancer specific anxiety state.
PSA, prostate-specific antigen.
